GDF2 and breast carcinoma: Specifically, GDF2 activation of SMAD1/5 signaling has been found to enhance cell death in ovarian and breast cancer cell lines; treatment of these cells with 5-azacytidine, a potent demethylating agent, demonstrated decreased methylation of the GDF2 locus, increased signaling and higher sensitivity to cell death [51].